I. Introduction: Discovery of an Endogenous Signal Peptide and Its Link to Aging
The discovery of GHK-Cu stemmed from a fundamental question regarding tissue repair: why do young tissues possess a healing capacity that is significantly superior to that of aging tissues? In 1973, while investigating active substances that affect both aged and young tissues, Pickart isolated a tripeptide-copper complex—with the sequence glycyl-L-histidyl-L-lysine—from human plasma. Subsequent research confirmed that GHK exhibits a strong affinity for copper ions; under physiological conditions, it primarily exists and functions as the GHK-Cu complex.
This discovery remains illuminating half a century later due to the strong negative correlation between plasma GHK concentrations and age: levels are approximately 200 ng/mL (10⁻⁷ M) at age 20 but drop to about 80 ng/mL by age 60—a decline of over 60%. This physiological reduction aligns closely in time with the loss of skin collagen, decreased elasticity, and diminished repair capacity. Consequently, GHK-Cu is understood as an endogenous “repair signal,” and its age-related depletion may constitute a key molecular basis for the phenotype of skin aging.
II. Molecular Signaling Mechanisms: The Dual-Track Action of Copper Ions and the Tripeptide Sequence
The mechanism of action of GHK-Cu cannot be summarized by a single pathway. Its biological activity is mediated by two structural components acting in synergy: the copper ion serves as an enzymatic cofactor involved in the covalent modification of matrix macromolecules, while the tripeptide sequence acts as a signal peptide regulating gene transcription programs.
Cofactor function of copper ions. Upon entering the cell, the Cu(II) ion within the GHK-Cu complex is released, providing an essential catalytic cofactor for the lysyl oxidase (LOX) family of enzymes. LOX catalyzes the oxidative deamination of lysine residues in collagen and elastin precursor molecules, generating aldehyde-containing cross-linking precursors; this is a critical covalent modification step for collagen fibers to acquire tensile strength and for elastin to gain its elastic recoil properties. Without the participation of copper ions, newly synthesized collagen molecules—while capable of being secreted into the extracellular matrix—cannot form stable cross-linked networks. Copper ions also serve as cofactors for superoxide dismutase (SOD), thereby participating in antioxidant defense. The significance of this “cofactor” role lies in the fact that GHK-Cu not only promotes the synthesis of matrix macromolecules but also ensures that these newly synthesized molecules possess the capacity for functional supramolecular assembly.
Gene regulatory function of the tripeptide sequence. The GHK tripeptide sequence itself acts as a signaling molecule, regulating extensive gene expression programs. Analyses based on the Broad Institute’s Connectivity Map reveal that, at nanomolar concentrations, GHK influences the expression of over 4,000 human genes—with 1,942 upregulated and 762 downregulated—representing approximately 31% of the expressed human genome. Upregulated genes are enriched in pathways related to antioxidant defense, DNA repair, and tissue remodeling, whereas downregulated genes are concentrated in pathways associated with inflammation and pro-fibrotic processes. In fibroblasts, GHK treatment recapitulates gene expression patterns induced by TGF-β, including the upregulation of actin cytoskeleton organization and integrin β1 expression.
The core of this “gene reprogramming” effect lies in GHK’s regulation of the TGF-β superfamily signaling pathways. GHK directly increases the expression of TGF-β and its family members, thereby activating repair programs. However, GHK’s regulatory activity is notably context-dependent: in both normal fibroblasts and keloid-derived fibroblasts, the copper-tripeptide complex reduces TGF-β1 secretion, suggesting a potential anti-scarring role in contexts of excessive fibrosis. A 2026 systematic review characterized this feature as “TGF-β3-mediated fibrosis inhibition,” meaning that while GHK-Cu promotes matrix synthesis, it avoids pathological fibrosis by biasing signaling output toward TGF-β3 rather than TGF-β1.
Release mechanism of matricryptins. GHK is not encoded by a standalone gene but is released via proteolysis from larger precursor proteins; its sequence is found within the collagen I α2 chain and the SPARC (secreted protein acidic and rich in cysteine) protein. When the extracellular matrix is degraded by proteases during injury or remodeling, GHK is released as a “matricryptin,” serving as a chemical signal of local tissue damage. This release mechanism imbues GHK-Cu with a unique biological logic: rather than being an exogenous drug, it is an endogenous repair signal generated upon tissue injury, and exogenous supplementation essentially compensates for a deficiency of this signal in aging tissues.
III. From Signaling to Remodeling: Skin Biological Effects of GHK-Cu
At the level of skin tissue, GHK-Cu’s gene regulatory program translates into a series of coordinated effects on matrix remodeling.
Multicomponent stimulation of extracellular matrix synthesis. GHK-Cu stimulates fibroblasts to synthesize mRNA and proteins for collagen types I and III, as well as elastin. Regarding proteoglycans, GHK-Cu specifically upregulates the expression of decorin while stimulating the synthesis of chondroitin sulfate and dermatan sulfate. Decorin is a small leucine-rich proteoglycan that functions not only in organizing the tissue matrix but also in regulating the bioavailability of profibrotic signals through its binding to TGF-β. The selective upregulation of decorin—as opposed to biglycan—by GHK-Cu demonstrates the fine molecular selectivity of its matrix regulation.
Coordinated regulation of matrix metalloproteinases and their inhibitors. GHK-Cu increases MMP-2 levels and mRNA expression in fibroblast-conditioned media while simultaneously boosting the secretion of TIMP-1 and TIMP-2. This coordinated regulatory pattern implies that GHK-Cu promotes matrix degradation activity while imposing corresponding inhibitory constraints, thereby keeping the remodeling process under control. MMP-2 targets substrates such as denatured collagen and type IV collagen; its activity facilitates the clearance of abnormal matrix deposits at injury sites, creating space for the orderly deposition of new matrix.
Anti-inflammatory and antioxidant effects. GHK-Cu suppresses the production of pro-inflammatory cytokines—such as TNF-α and IL-6—by inhibiting NF-κB p65 phosphorylation and the p38 MAPK signaling pathway, while simultaneously increasing the expression of the anti-inflammatory cytokine IL-10. Regarding antioxidant activity, GHK-Cu enhances SOD activity and reduces reactive oxygen species (ROS) levels. Collectively, these effects establish a microenvironment that promotes repair and inhibits damage, facilitating the transition of fibroblasts from an inflammatory state to a synthetic phenotype.
Functional enhancement of collagen cross-linking. The aforementioned role of copper ions as cofactors for LOX means that GHK-Cu’s effects extend beyond merely stimulating synthesis. A 2025 study utilizing a Golgi-targeted copper delivery system confirmed that GHK-Cu significantly enhances LOX activity and collagen cross-linking. This finding holds significant functional implications: simply increasing the quantity of synthesized collagen is insufficient to improve skin mechanical properties; newly synthesized collagen must undergo LOX-mediated cross-linking to form a fibrous network capable of withstanding tensile stress. GHK-Cu’s ability to deliver copper ions renders it indispensable during this critical post-synthetic modification step. IV. Conclusion
The biological narrative of GHK-Cu is remarkably comprehensive: originating from an endogenous tripeptide inversely correlated with age, it operates through mechanisms involving copper-mediated enzymatic cofactor activity and tripeptide-driven, broad-spectrum gene regulation, ultimately converging on multidimensional, synergistic effects—including extracellular matrix synthesis, cross-linking, and degradation, as well as anti-inflammatory action. Each link in this mechanistic chain is supported by robust preclinical evidence.
